This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback